Maravai LifeSciences is no longer the pandemic capping vendor that printed windfall CleanCap sales and then watched that demand vanish. Under Bernd Brust, who took the chief executive role last year, the company cut about 25% of its workforce and is now trying to prove that a smaller TriLink-plus-Cygnus tools platform can grow on discovery mRNA and clinical-grade reagents rather than one-off vaccine fills. The latest quarter is the first clean look at that smaller company without another high-volume COVID CleanCap order.
The tension is that profitability is healing much faster than the top line. Adjusted earnings before interest, taxes, depreciation, and amortization, a non-GAAP operating-profit proxy, flipped to a gain of about $9 million from a year-ago loss, and management lifted full-year guidance on that measure into the low thirties of millions. Revenue guidance stayed put in a band around $210 million because large GMP, or good-manufacturing-practice, orders and contract-development work still slip between quarters. Cash fell as the June refinancing prepaid older term debt that had been due later this decade. The company left roughly $70 million of cash against about $147 million of remaining borrowings.
What the quarter actually tests is whether discovery-to-clinic conversion, not another vaccine refill, can carry the franchise. GMP consumables jumped on clinical CleanCap and a first enzyme order, ModTail crossed more than one hundred active users, and Cygnus posted a fifth straight growth quarter. The open question is whether those conversion steps compound through the second half without another lumpy order, or whether the raised profit guide is just the cost cut showing through on a still-thin revenue base.